ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
Insilico Medicine's experimental drug rentosertib, developed for idiopathic pulmonary fibrosis, appeared to make patients biologically younger in a clinical trial. The treatment targets a disease that progressively scars the lungs.
Tap to vote and see what everyone thinks.
Summary by ByteBrief